Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SkyWest Inc (SKYW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs SkyWest Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while SkyWest Inc trades at $96.74 (market cap $3.88B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | SKYW | |
|---|---|---|
Market Cap | $4.49B | $3.88B |
Sector | Health | Technology |
52-Week High | $28.06 | $123.72 |
52-Week Low | $20.06 | $78.40 |
Enterprise Value | $3.69B | $5.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SkyWest (SKYW) trades at $98.75, up 1.93% with a bullish technical signal supported by moving averages. The stock shows attractive valuation with P/E of 9.47 and P/S of 0.99, while maintaining strong profitability with 10.42% net margin and 16.5% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains stable revenue around $4.1B with consistent cash flow generation from operations exceeding $900M annually.
The outlook remains positive with 56% analyst buy ratings and $109.33 consensus price target suggesting 11% upside. Key risks include rising fuel costs impacting airline profitability and negative net cash flow trends. The upcoming Q2 2026 earnings call on July 23 will be crucial for confirming growth trajectory amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
